Nagpheni juice in anemia

Experimental and clinical studies on Nagapheni (Opuntia elatior Mill.), an anukta dravya (extra-pharmacopoeial drug), with special reference to its Haematinic activity

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/011743

Enrollment

100

Registered

2018-02-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients between age of 18-60 years Male and female patients diagnosed cases of Pandu (Iron deficiency anaemia) 8-10 g% of Hb% or reduced RBC count

Interventions

Intervention1: Nagpheni Opuntia elatior Mill juice: Nagpheni juice 20 ml two times before meal for 60 days Control Intervention1: Tab. Punarnava mandura: Tab Punarnava mandura 2gm two time before meal

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between age of 18-70 years 2. Patients of both gender 3. Diagnosed cases of Pandu (iron deficiency anaemia) 4. Patients having Hb% in between 8-10 g 5. Patients with reduced RBC count

Exclusion criteria

Exclusion criteria: 1. Age less than 18 years and more than 70 years. 2. Pregnant women and lactating mothers. 3. Cases of Chronic Renal (CRF)/ 4. Cases of Chronic Hepatic diseases, Cardiac diseases(CCF) and Cancer 5. Any continuing blood loss e.g., Hematemesis, Melaena, Bleeding piles etc. having Hb% less than 7g% 6. Patients consuming alcohol 7. Patients those are on steroids treatment 8. Patients with treatment of any haematinic drug(Ayurveda/modern) within last two months 9. Minimum wash out period of two months if patients are under previous therapy.

Design outcomes

Primary

Measure	Time frame
to increase hemoglobin levelTimepoint: To attend 10gm % of Haemoglobinlevel after 2 month of trial drug Opuntia elatior Mill.	—

Secondary

Measure	Time frame
to improve QOL of patientTimepoint: To increase serum ferritin level Improvement of the quality of life of the patients (to be assessed as per WHO criteria) Development of a new drug for easy palatable administration.	—

Countries

India

Contacts

Public ContactProf R N Acharya

IPGT and RA Gujarat Ayurved university

rnacharya@ayurveduniversity.com2882552014

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026